BIOTECHNOLOGY ASSETS, S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.325 EUR | -2.69% |
|
-0.91% | -17.93% |
| 04-05 | Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 65.78 | 80.24 | 21.78 | 20.94 | 12.42 | 22.85 |
| Enterprise Value (EV) 1 | 85.69 | 137.8 | 28.36 | 27.47 | 19.87 | 26.57 |
| P/E ratio | -3.92 x | -7.93 x | -2.53 x | -6.95 x | -6.41 x | 14.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.61 x | 1.83 x | 7.53 x | 6.38 x | 4.2 x | 5.85 x |
| EV / Revenue | 3.4 x | 3.14 x | 9.81 x | 8.37 x | 6.72 x | 6.8 x |
| EV / EBITDA | -5.81 x | -18.1 x | -168 x | -26.3 x | -27.9 x | 7.14 x |
| EV / FCF | -4.99 x | -6.79 x | 2.8 x | -15.5 x | -20.4 x | 10.6 x |
| FCF Yield | -20.1% | -14.7% | 35.7% | -6.45% | -4.9% | 9.41% |
| Price to Book | 3.07 x | 10.4 x | 5.46 x | 4.66 x | 3.1 x | 3.42 x |
| Nbr of stocks (in thousands) | 39,389 | 39,336 | 39,169 | 45,613 | 54,011 | 57,698 |
| Reference price 2 | 1.670 | 2.040 | 0.5560 | 0.4590 | 0.2300 | 0.3960 |
| Announcement Date | 19-04-12 | 20-06-22 | 21-05-11 | 22-04-13 | 23-04-11 | 24-04-05 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 25.23 | 43.89 | 2.892 | 3.282 | 2.958 | 3.908 |
| EBITDA 1 | -14.74 | -7.628 | -0.1693 | -1.043 | -0.7111 | 3.722 |
| EBIT 1 | -16.57 | -10.45 | -1.213 | -2.075 | -1.736 | 2.708 |
| Operating Margin | -65.68% | -23.8% | -41.96% | -63.22% | -58.71% | 69.28% |
| Earnings before Tax (EBT) 1 | -16.81 | -9.994 | -1.555 | -2.91 | -2.043 | 2.322 |
| Net income 1 | -16.69 | -10.08 | -8.607 | -3.013 | -1.943 | 1.574 |
| Net margin | -66.17% | -22.97% | -297.64% | -91.8% | -65.7% | 40.27% |
| EPS 2 | -0.4261 | -0.2574 | -0.2196 | -0.0661 | -0.0359 | 0.0273 |
| Free Cash Flow 1 | -17.18 | -20.31 | 10.12 | -1.772 | -0.9739 | 2.5 |
| FCF margin | -68.1% | -46.26% | 350.04% | -53.98% | -32.93% | 63.97% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 67.17% |
| FCF Conversion (Net income) | - | - | - | - | - | 158.86% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-04-12 | 20-06-22 | 21-05-11 | 22-04-13 | 23-04-11 | 24-04-05 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 19.9 | 57.5 | 6.59 | 6.53 | 7.45 | 3.72 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.351 x | -7.544 x | -38.91 x | -6.261 x | -10.47 x | 0.9991 x |
| Free Cash Flow 1 | -17.2 | -20.3 | 10.1 | -1.77 | -0.97 | 2.5 |
| ROE (net income / shareholders' equity) | -93.6% | -79.8% | -29.9% | -73.7% | -47.3% | 30.2% |
| ROA (Net income/ Total Assets) | -16.4% | -7.59% | -1.34% | -6.47% | -5.66% | 9.65% |
| Assets 1 | 101.9 | 132.8 | 640.6 | 46.57 | 34.34 | 16.31 |
| Book Value Per Share 2 | 0.5400 | 0.2000 | 0.1000 | 0.1000 | 0.0700 | 0.1200 |
| Cash Flow per Share 2 | 0.1000 | 0.1200 | 0.0100 | 0.0400 | 0.0100 | 0.0100 |
| Capex 1 | 9.62 | 6.07 | 0 | 0.02 | 0.13 | 0.07 |
| Capex / Sales | 38.12% | 13.84% | 0.15% | 0.52% | 4.31% | 1.78% |
| Announcement Date | 19-04-12 | 20-06-22 | 21-05-11 | 22-04-13 | 23-04-11 | 24-04-05 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.93% | 20.72M | |
| +2.93% | 108B | |
| -3.29% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- BST Stock
- Financials Biotechnology Assets, S.A.